Navigation Links
Spherix Announces Third Quarter Financial Results
Date:11/11/2011

BETHESDA, Md., Nov. 11, 2011 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today reported financial results for the three and nine months ended September 30, 2011.

Recent and Upcoming Highlights

  • Pharmaceutical Development
  • Reported that SPX-106T, a combination of SPX-106 with D-tagatose, reduced dyslipidemia in new studies of apolipoprotein E-deficient mice and Syrian Golden hamsters, which also corroborated data obtained in LDL receptor-deficient mice
  • Reported that a new study in rats demonstrated that D-tagatose inhibits fructose absorption in the gastrointestinal tract, and this finding provides further insight into the mechanism of action of SPX-106T
  • Reported that SPX-106T reduced VLDL and LDL in LDL receptor-deficient mice, as well as atherosclerotic lesion area in the aortic arch to less than one-half the value of the untreated group
  • Continued research contracts to investigate the role of D-tagatose in lowering triglycerides
  • Continued preclinical testing of SPX106T for treatment of high triglycerides and cholesterol, atherosclerosis and the metabolic syndrome

  • Health Sciences Consulting
  • Recent and upcoming trade and professional shows:
  • August 17, 2011: Dr. Kruger presented "Regulatory Pathways to Market: A Discussion of Dietary Supplements, Medical Food, and Nutraceuticals," at the Pharmaceutical Education & Research Institute, Inc. (PERI)'s Webinar
  • August 2011 publication: Kruger, C.L., Booth, N. and Hayes, A.W., "Policing Ourselves: Is GRAS Robust Enough?," Food Technology, pages 18-19
  • September 8, 2011:  Spherix Consulting pre
    '/>"/>

  • SOURCE Spherix Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds
    2. Spherix to Raise $1.25 Million in Private Placement
    3. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
    4. Spherix Announces Annual Shareholders Meeting Date
    5. Spherix to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
    6. Spherix Regains Compliance With NASDAQ Listing Rule
    7. Spherix Announces First Quarter Financial Results
    8. Spherix Announces Reverse Stock Split Effective May 6, 2011
    9. Spherix to Effect Reverse Stock Split
    10. Spherix Announces 2010 Financial Results
    11. Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... ... July 30, 2015 , ... ... Francois Vieillard as Sales & Marketing Director. , With more than 25 ... be responsible for reinforcing Tronics’ business development activities worldwide. He brings to the ...
    (Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
    (Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
    (Date:7/30/2015)... the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online ... contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... in Dallas, TX , ISN has additional offices in Calgary ...
    Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
    ... Mass.--Folding paper into shapes such as a crane or ... imagine trying to fold something that,s about a hundred ... it to use as an electronic device. , ... professor of mechanical engineering, is developing the basic principles ...
    ... Inc. (NASDAQ: VSGN ; TSX:VAS) today reported the results ... All dollar amounts referenced herein are in Canadian dollars unless ... cash equivalents totaled $8.6 million, compared with $23.5 million at ... As of January 31, 2009, our cash balance was $8.5 ...
    ... Feb. 27 Arkion(R) Life Sciences has received a ... Treatment in Louisiana effective March 1, 2009. The EPA ... protect field and sweet corn from marauding blackbirds and ... Avitec, Avipel(R) is applied to corn seed before planting ...
    Cached Biology Technology:MIT uses nano-origami to build tiny electronic devices 2MIT uses nano-origami to build tiny electronic devices 3Vasogen Announces 2008 Year-End Results 2Vasogen Announces 2008 Year-End Results 3Vasogen Announces 2008 Year-End Results 4Vasogen Announces 2008 Year-End Results 5Vasogen Announces 2008 Year-End Results 6Vasogen Announces 2008 Year-End Results 7Vasogen Announces 2008 Year-End Results 8Vasogen Announces 2008 Year-End Results 9Vasogen Announces 2008 Year-End Results 10Vasogen Announces 2008 Year-End Results 11Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana 2
    (Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
    (Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
    (Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
    Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
    ... Strasbourg 18/04/12 - Technology has transformed the way humans interact ... big ideas that will drive growth in marine and maritime ... and policy will gather at the 3rd Marine Board Forum ... Marine Board has convened this flagship event on the understanding ...
    ... April 2012 -- Several new studies that may help ... individual patients and of their tumors are being presented ... "A major goal of lung cancer treatment is ... Fiona Blackhall from The Christie NHS Foundation Trust in ...
    ... can be used to boost an enzyme,s function by as much ... detergents and a host of other products. In a paper ... team led by Pratul Agarwal of the Department of Energy,s Oak ... nature and it happens in the blink of an eye. ...
    Cached Biology News:New technologies for a blue future 2Advances in personalized medicine for lung cancer 2Advances in personalized medicine for lung cancer 3Advances in personalized medicine for lung cancer 4Advances in personalized medicine for lung cancer 5ORNL process improves catalytic rate of enzymes by 3,000 percent 2
    Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
    Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
    Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
    Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
    Biology Products: